Anika Therap
ANIK18.07011.75% ( +1.900 )
Q2 FY2026 EarningsQ2 FY26 revenue reached $32.6M, up 16% YoY. Commercial Channel revenue grew 17% YoY to a record $13.9M, while OEM grew 14% to $18.7M. Gross margin significantly expanded to 65.0% (up 14.0pct). Net income turned positive at $3.3M with diluted EPS of $0.24, and Adjusted EBITDA reached a multi-year high of $7.1M (22% margin). Full-year FY26 revenue growth guidance was raised to 5-10% and Adjusted EBITDA margin to 13-17%.
Financial report interval: 2026.03.30 - 2026.06.30
Preview: Anika Therap(ANIK) predict that the Revenue is 32.61 M (+15.56%), Beat estimate;the EBIT is 2.954 M (+170.7%), Beat estimate;the EPS is 0.24 (+185.7%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.03B15.56%
0.03B3.53%
+0.00B12.03%
EBITExceed expectations
0.00B170.67%
-0.00B26.66%
+0.01B144.01%
EPSExceed expectations
0.24185.71%
-0.17537.50%
+0.4150148.21%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf